Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-05-27
2008-05-27
Haddad, Maher M. (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100, C530S388150, C530S388220
Reexamination Certificate
active
11145001
ABSTRACT:
The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to CD64 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating autoimmune disorders, transplant rejection, Graft Versus Host Disease, or cancer and for enhanced presentation of antigen using conjugates of an antigen and an anti-CD64 antibody.
REFERENCES:
patent: 6682928 (2004-01-01), Keler et al.
patent: 2003/0039641 (2003-02-01), Keler et al.
patent: WO 94/10332 (1994-05-01), None
patent: WO 98/24884 (1998-06-01), None
patent: WO 01/14424 (2001-03-01), None
Rudikoff et al. PNAS 1982, 79 :1979-1983.
Li et al. Biochemistry 2000. 39:6296-6309.
Brummell et al. Biochemistry 1993, 32:1180-1187.
Kobayaski et al. Protein Engineering 1999, 12;10:879-884.
Burks et al. PNAS 1997, 94:412-417.
Liu, Chunlei et al., FcγRI-Targeted Fusion Proteins Result in Efficent Presentation by Human Monocytes of Antigenic and Antagonist T Cell Epitopes,J. Clin. Invest.,vol. 98(9):2001-2007 (Nov. 1996).
Heijnen, Ingmar A.F.M. et al., “Antigen Targeting to Myeloid-specific Human FcγRI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice,”J. Clin. Invest.,vol. 97(2):331-338 (Jan. 1996).
Lonberg, Nils et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications,”Letters to Nature,vol. 368 pp. 856-859 (Apr. 1994).
Fishwild, Dianne M. et al., “High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice,”Nature Biotechnology,vol. 14, pp. 845-851 (Jul. 1996).
Wallace, Paul K. et al., “FcγRI blockade and modulation for immunotherapy,”Cancer Immunol Immunother,vol. 45, pp. 137-141 (1997).
Wiener, E. et al., “HPA-Ia-mediated platelet interaction with monocytes in vitro: Involvement of Fcγ receptor (FcγR) classes and inhibition by humanised monoclonal anti-FcγRI H22,”European Journal of Haematology,vol. 65, pp. 399-406 (2000).
Graziano, Robert F. et al., “Construction and Characterization of a Humanized Anti-γ-lg Receptor Type I (FcγRI) Monoclonal Antibody,”The Journal of Immunology,vol. 455, pp. 4996-5002 (1995).
Graziano Robert
Sundarapandiyan Karuna
Dahle Chun
Haddad Maher M.
Lahive & Cockfield LLP
Medarex Inc.
Remillard, Esq. Jane E.
LandOfFree
Human monoclonal antibodies to Fc gamma receptor I (CD64) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human monoclonal antibodies to Fc gamma receptor I (CD64), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibodies to Fc gamma receptor I (CD64) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3914575